Thomas John Check, MD | |
2500 S Woodworth Loop, Palmer, AK 99645-8984 | |
(907) 861-6000 | |
Not Available |
Full Name | Thomas John Check |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2500 S Woodworth Loop, Palmer, Alaska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1306974191 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 4529 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Thomas John Check, MD Po Box 718, Palmer, AK 99645-0718 Ph: (907) 746-7511 | Thomas John Check, MD 2500 S Woodworth Loop, Palmer, AK 99645-8984 Ph: (907) 861-6000 |
News Archive
The New York Times: "Democrats now say they see little chance of the minority's cooperation in approving any overhaul, and are increasingly focused on drawing support for a final plan from within their own ranks. Top Democrats said Tuesday that their go-it-alone view was being shaped by what they saw as Republicans' purposely strident tone against health care legislation during this month's Congressional recess, as well as remarks by leading Republicans that current proposals were flawed beyond repair."
A new treatment for prostate cancer may provide a distinct advantage over other conventional protocols and induce actual regression of the disease - not just relief from bone pain or a limited control of the disease.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
› Verified 7 days ago
Kevin D Delduca, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Meghan L Lindstrom, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Thomas W Quimby, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6620 | |
Michael Robert Alter, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
David Anderson Grove Jr., MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Thomas Edward Leigh, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 |